Brokers Set Expectations for ATRA Q1 Earnings

Key Points

• HC Wainwright projects that Atara Biotherapeutics will achieve earnings of $2.46 per share for Q1 2026, despite the overall full-year estimate being a loss of ($10.39) per share.
• Atara Biotherapeutics' recent quarterly earnings surpassed expectations, reporting $0.19 EPS compared to the consensus estimate of (0.32), with revenue significantly higher at $17.58 million.
• Major shareholder Innovation Ltd Panacea acquired 55,000 shares of Atara Biotherapeutics stock, increasing their stake by 4.07% and raising their total ownership value to approximately $17.1 million.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) - HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Atara Biotherapeutics in a report released on Tuesday, August 19th. HC Wainwright analyst R. Burns forecasts that the biotechnology company will earn $2.46 per share for the quarter. The consensus estimate for Atara Biotherapeutics' current full-year earnings is ($10.39) per share. HC Wainwright also issued estimates for Atara Biotherapeutics' Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.52) EPS and Q4 2026 earnings at ($0.49) EPS.

Atara Biotherapeutics Stock Performance

NASDAQ:ATRA opened at $11.48 on Wednesday. The stock has a fifty day moving average price of $9.92 and a two-hundred day moving average price of $8.17. The stock has a market capitalization of $80.59 million, a price-to-earnings ratio of -26.70 and a beta of 0.26. Atara Biotherapeutics has a 1 year low of $5.01 and a 1 year high of $18.70.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.51. The firm had revenue of $17.58 million during the quarter, compared to analysts' expectations of $4.23 million. Atara Biotherapeutics had a negative return on equity of 8.34% and a net margin of 3.07%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new position in Atara Biotherapeutics in the second quarter worth $31,000. Marshall Wace LLP acquired a new stake in Atara Biotherapeutics in the second quarter valued at $327,000. Geode Capital Management LLC grew its holdings in Atara Biotherapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company's stock valued at $464,000 after purchasing an additional 1,457 shares during the last quarter. EcoR1 Capital LLC grew its holdings in Atara Biotherapeutics by 7.7% in the first quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company's stock valued at $3,405,000 after purchasing an additional 41,049 shares during the last quarter. Finally, Staley Capital Advisers Inc. grew its holdings in Atara Biotherapeutics by 60.0% in the first quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company's stock valued at $475,000 after purchasing an additional 30,000 shares during the last quarter. Hedge funds and other institutional investors own 70.90% of the company's stock.

Insider Transactions at Atara Biotherapeutics

In other Atara Biotherapeutics news, major shareholder Innovation Ltd Panacea acquired 55,000 shares of the business's stock in a transaction on Friday, August 15th. The stock was purchased at an average price of $12.19 per share, for a total transaction of $670,450.00. Following the completion of the transaction, the insider owned 1,405,000 shares of the company's stock, valued at $17,126,950. The trade was a 4.07% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.00% of the company's stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.